FIELD: medicine.
SUBSTANCE: there are described target-specific compounds representing glucagon-like protein-1 (GLP-1R) receptor agonist conjugates with a linker covalently bound with an antigen-binding antibody site. The invention also refers to methods for preventing or treating diabetes or diabetes-associated conditions.
EFFECT: compounds maintain insulnotropic activity combined with manifestation of prolonged elimination half-life.
39 cl, 44 dwg, 4 tbl, 29 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN EZH2 INHIBITORS AND METHODS OF APPLICATION THEREOF | 2011 |
|
RU2618475C2 |
| HUMAN EZH2 INHIBITORS AND METHODS FOR APPLICATION THEREOF | 2011 |
|
RU2765155C2 |
| ANTIANGIOGENIC COMPOUNDS | 2007 |
|
RU2418003C2 |
| PREFERENTIAL PAIRING OF ANTIBODY DOMAIN | 2018 |
|
RU2792440C2 |
| CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | 2015 |
|
RU2678810C2 |
| MULTICOMPONENT COMPOUND BASED ON EPOXY RESIN WITH LEAKAGE INDICATOR, AND CURING COMPONENT FOR COMPOUND BASED ON EPOXY RESIN | 2018 |
|
RU2783623C2 |
| SUBSTITUTED BICYCLIC IMDAZO-3-YLAMINES SUITABLE FOR REGULARING mGluR5-RECEPTOR | 2005 |
|
RU2435770C2 |
| ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY | 2014 |
|
RU2679715C1 |
| ESTERASES AND USE THEREOF | 2020 |
|
RU2829537C2 |
| COVALENT BONDED POLYPEPTIDE TOXIN AND ANTIBODY CONJUGATES | 2014 |
|
RU2682754C2 |
